Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Annamycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors
    Moleculin's Annamycin Phase 2 AML Data Surpasses Top Competitors

    08 Jan 2025

    // #N/A

    https://www.prnewswire.com/news-releases/moleculin-highlights-development-progress-of-annamycin-phase-2-data-outperforms-billion-dollar-assets-in-aml-phase-3-data-readouts-in-2025--2026-302345069.html

    #N/A
    08 Jan 2025
    Share Share
    Moleculin Reports Q2 2024 Results And Provides Corporate Update
    Moleculin Reports Q2 2024 Results And Provides Corporate Update

    14 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302221619.html

    PR NEWSWIRE
    14 Aug 2024
    Share Share
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML
    Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML

    10 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-completes-end-of-phase-2-meeting-with-fda-for-annamycin-in-aml-302192692.html

    PR NEWSWIRE
    10 Jul 2024
    Share Share
    Moleculin US Patent For Annamycin Lipid Delivery Tech
    Moleculin US Patent For Annamycin Lipid Delivery Tech

    09 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-us-patent-issue-notification-for-lipid-based-delivery-technology-for-annamycin-302140466.html

    PR NEWSWIRE
    09 May 2024
    Share Share
    Moleculin Presents Positive Annamycin Data
    Moleculin Presents Positive Annamycin Data

    10 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-positive-data-demonstrating-high-anti-cancer-activity-of-annamycin-and-non-cardiotoxic-properties-302112418.html

    PR NEWSWIRE
    10 Apr 2024
    Share Share
    Moleculin Announces Positive Data in Annamycin MB-106 Phase 1B/2 AML Trial
    Moleculin Announces Positive Data in Annamycin MB-106 Phase 1B/2 AML Trial

    25 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/moleculin-announces-positive-interim-data-in-annamycin-mb-106-phase-1b2-aml-trial-302097561.html

    PR NEWSWIRE
    25 Mar 2024
    Share Share